CRISPR-based medicines are racing towards the clinic, barely a blink of an eye since scientists reported in 2013 that the gene-editing tool could be used to cut DNA in human cells. Biotech firms including Editas Medicine, CRISPR Therapeutics and Intellia Therapeutics are all ramping up for first-in-human trials, likely to start next year. For Katrine Bosley, CEO of Editas and fast-car aficionado, this breakneck development trajectory has made for an exciting ride. She spoke with Asher Mullard about the technological tractability of CRISPR, the future of the modality and the importance of engaging in ethical debates about the use of the gene-editing technology.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Katrine Bosley. Nat Rev Drug Discov 16, 672–673 (2017). https://doi.org/10.1038/nrd.2017.191
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.191
